The present invention relates to a composition for detecting nucleic acid comprising duplex molecular beacon and graphene oxide and a colorimetric signal enhancement method of detecting nucleic acid using the same. According to the composition, kit and method for detecting nucleic acid of the present invention, a complex can be formed by adsorbing a single strand having a DNAzyme sequence dissociated from the conjugate of a duplex molecular beacon and a target nucleic acid to the graphene oxide surface, and separated, and a colorimetric signal amplified therefrom can be induced, so that a very low concentration of target nucleic acid can be detected with high efficiency and the target nucleic acid can be detected quickly and easily in seconds. Therefore, a new colorimetric target nucleic acid detection system capable of point of care testing (POCT) can be provided.

The present application relates to a biosensor for detecting an analyte comprising a first and second working electrode; a detection probe functionalized on the first working electrode, the detection probe comprising a reporter moiety and a recognition moiety for an analyte; a capture probe functionalized on the second working electrode; and a counter electrode. Each working electrode is configured to provide a change in signal if the analyte is present. The biosensor can be used to detect an analyte in a sample.

The present application relates to a biosensor for detecting an analyte comprising a first and second working electrode; a detection probe functionalized on the first working electrode, the detection probe comprising a reporter moiety and a recognition moiety for an analyte; a capture probe functionalized on the second working electrode; and a counter electrode. Each working electrode is configured to provide a change in signal if the analyte is present. The biosensor can be used to detect an analyte in a sample.

This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analytes.

This disclosure relates to particles conjugated to therapeutic nucleic acids. In certain embodiments, the nucleic acid comprises a sequence that catalytically cleaves RNA, e.g., DNAzyme or RNAzyme. In certain embodiments, the particles contain nucleic acids with both DNAzyme and/or RNAzyme and siRNA sequences. The cleaving nucleic acids optionally comprise a sequence functioning to hybridize to a target of interest and/or the particles are further conjugated to a targeting moiety. In certain embodiments, conjugated particles are used in the treatment or prevention of cancer or viral infections or bacterial infections. In certain embodiments, conjugated particles are used in detecting metal ions and other small molecule analytes.

The present invention relates to a porous substrate comprising at least one active agent entrapped within said pores of said substrate; wherein said pores are capped by at least one nucleic acid sequence; said agent is being released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore. The invention further relates to methods of manufacturing said substrate, uses thereof for the controlled administration of active agents and diagnostic of conditions in a patient.

The present invention relates to a porous substrate comprising at least one active agent entrapped within said pores of said substrate; wherein said pores are capped by at least one nucleic acid sequence; said agent is being released by a triggered reaction of said capping sequence with at least one analyte (biomarker) thereby allowing said capping to be cleaved from said pore. The invention further relates to methods of manufacturing said substrate, uses thereof for the controlled administration of active agents and diagnostic of conditions in a patient.

The present invention provides oligonucleotides and methods for their use in the detection and/or differentiation of target nucleic acids. The oligonucleotides and methods find particular application in amplifying, detecting, and/or discriminating multiple targets simultaneously.

The present invention provides oligonucleotides and methods for their use in the detection and/or differentiation of target nucleic acids. The oligonucleotides and methods find particular application in amplifying, detecting, and/or discriminating multiple targets simultaneously.

The present invention provides a novel nucleic acid element candidate molecule for use in screening for a nucleic acid element for target analysis and a novel screening method for screening for a nucleic acid element for target analysis using the same. The candidate molecule according to the present invention is a molecule for screening for a nucleic acid element for target analysis, being the following single-stranded nucleic acid (I): (I) a single-stranded nucleic acid comprising a catalyst sequence (D), a blocking sequence (B), and a binding sequence (A) that binds to a target, linked in this order. The blocking sequence (B) is complementary to a partial region (Dp) in the catalyst sequence (D). A terminal region (Ab) on the blocking sequence (B) side in the binding sequence (A) is complementary to a flanking region (Df) of the partial region (Dp) in the catalyst sequence (D) and is complementary to a terminal region (Af) on the side opposite to the blocking sequence (B) side in the binding sequence (A).